Covance (CVD) Getting Somewhat Positive News Coverage, Accern Reports

Media stories about Covance (NYSE:CVD) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Covance earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media stories about the healthcare company an impact score of 47.0939499662733 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Covance (CVD) remained flat at $$107.07 on Tuesday. The firm has a market cap of $6,060.00 and a PE ratio of 33.05.

WARNING: “Covance (CVD) Getting Somewhat Positive News Coverage, Accern Reports” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/16/covance-cvd-getting-somewhat-positive-news-coverage-accern-reports.html.

About Covance

Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.

Insider Buying and Selling by Quarter for Covance (NYSE:CVD)

Receive News & Ratings for Covance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply